Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Deficiency of plasma platelet-activating factor acetylhydrolase: roles of blood cells.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Lack of evidence for associations between plasma platelet-activating factor acetylhydrolase deficiency and schizophrenia.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
Study of platelet-activating factor acetylhydrolase in the perioperative period of patients undergoing cardiac surgery.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice.
1-alkyl-2-acetylglycerophosphocholine esterase deficiency
[Plasma platelet-activating factor acetylhydrolase (PAF-AH) deficiency as a risk factor for stroke]
Abetalipoproteinemia
Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.
Acquired Immunodeficiency Syndrome
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Acute Coronary Syndrome
Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.
Acute Coronary Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Acute Coronary Syndrome
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Acute Coronary Syndrome
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Acute Coronary Syndrome
Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome.
Acute Coronary Syndrome
Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.
Acute Coronary Syndrome
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.
Acute Coronary Syndrome
Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome?
Acute Coronary Syndrome
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Acute Coronary Syndrome
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
Acute Coronary Syndrome
Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China.
Acute Coronary Syndrome
Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
Acute Coronary Syndrome
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Acute Coronary Syndrome
Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke.
Acute Coronary Syndrome
Lp-PLA2: a new kid on the block.
Acute Coronary Syndrome
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Acute Coronary Syndrome
Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.
Acute Coronary Syndrome
Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.
Acute Coronary Syndrome
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Acute Coronary Syndrome
Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk.
Acute Coronary Syndrome
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Acute Coronary Syndrome
Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
Acute Coronary Syndrome
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Acute Coronary Syndrome
The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
Acute Kidney Injury
The role of lipoprotein-associated phospholipase A2 in acute kidney injury of septic mice.
Acute Lung Injury
DIFFERENTIAL EXPRESSION OF PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE IN LUNG MACROPHAGES.
Acute Lung Injury
Lung production of platelet-activating factor acetylhydrolase in oleic acid-induced acute lung injury.
Adenocarcinoma
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Adenocarcinoma
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
Adenomatous Polyposis Coli
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Aggressive Periodontitis
Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis.
Aggressive Periodontitis
Differential platelet-activating factor synthesis by monocytes and polymorphonuclear leukocytes from subjects with localized aggressive periodontitis.
Albuminuria
Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetes.
Albuminuria
[Informatori biologici per ischemia miocardica silente: approccio diagnostico e prognostico.]
Alopecia
ROBO4 deletion ameliorates PAF-mediated skin inflammation via regulating the mRNA translation efficiency of LPCAT1/LPCAT2 and the expression of PAF receptor.
Alzheimer Disease
A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease.
Alzheimer Disease
Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Alzheimer Disease
Genetic deficiency of plasma lipoprotein-associated phospholipase A2 (PLA2G7 V297F null mutation) and risk of Alzheimer's disease in Japan.
Alzheimer Disease
Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [(18)F]GSK2647544 in Healthy Male Subjects.
Alzheimer Disease
Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease.
Alzheimer Disease
Lipoprotein-associated phospholipase A2: The story continues.
Alzheimer Disease
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease.
Alzheimer Disease
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
Alzheimer Disease
Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
Alzheimer Disease
Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Anaphylaxis
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014.
Anaphylaxis
Anaphylactic reaction induced by Toxoplasma gondii-derived heat shock protein 70.
Anaphylaxis
Basal platelet-activating factor acetylhydrolase: Prognostic marker of severe Hymenoptera venom anaphylaxis.
Anaphylaxis
Clinical significance of plasma PAF acetylhydrolase activity measurements as a biomarker of anaphylaxis: Cross-sectional study.
Anaphylaxis
Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.
Anaphylaxis
Effect of human plasma-type platelet-activating factor acetylhydrolase in two anaphylactic shock models.
Anaphylaxis
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
Anaphylaxis
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
Anaphylaxis
Pathophysiology of food-induced anaphylaxis.
Anaphylaxis
Platelet-activating factor, PAF acetylhydrolase, and anaphylaxis.
Anaphylaxis
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
Anaphylaxis
Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis.
Anaphylaxis
Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.
Angina Pectoris
Lipoprotein-associated phospholipase A2 (Lp-PLA2) - possible diagnostic and risk biomarker in chronic ischaemic heart disease.
Angina, Stable
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Angina, Stable
Association between Lp-PLA2 and coronary heart disease in Chinese patients.
Angina, Stable
Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Angina, Stable
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.
Angina, Stable
Platelet-activating factor acetylhydrolase activity in patients with chronic stable angina (preliminary results).
Angina, Stable
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Angina, Stable
Platelet-associated and secreted PAF-acetylhydrolase activity in patients with stable angina: sequential changes of the enzyme activity after angioplasty.
Angina, Stable
Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina.
Angina, Unstable
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Angina, Unstable
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Angina, Unstable
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Angina, Unstable
Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
Angioedema
Hereditary angioedema attack: what happens to vasoactive mediators?
Antiphospholipid Syndrome
Platelet-activating factor acetylhydrolase in primary antiphospholipid syndrome.
Aortic Aneurysm
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Aortic Aneurysm, Abdominal
Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese.
Aortic Aneurysm, Abdominal
Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: A prospective longitudinal cohort study.
Aortic Valve Disease
Circulating Lp-PLA2 is associated with high valvuloarterial impedance and low arterial compliance in patients with aortic valve bioprostheses.
Aortic Valve Disease
Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization.
Aortic Valve Stenosis
Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study.
Aortic Valve Stenosis
Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans.
Aortic Valve Stenosis
Lipoprotein-associated phospholipase A2 and aortic stenosis: biomarker or new target for an old foe?
Aortic Valve Stenosis
Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis.
Arteritis
Effect of Treatment for 12 weeks with Rilapladib, a Lipoprotein-associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed with 18F-Fluorodeoxyglucose-PET Imaging.
Arthritis
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Arthritis, Juvenile
Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity.
Arthritis, Rheumatoid
Atherosclerosis assessment and rheumatoid arthritis.
Arthritis, Rheumatoid
Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases.
Arthritis, Rheumatoid
Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?
Arthritis, Rheumatoid
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Arthritis, Rheumatoid
Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
Arthritis, Rheumatoid
Release of platelet-activating factor in systemic lupus erythematosus.
Asthma
Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.
Asthma
Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.
Asthma
Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma.
Asthma
Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma.
Asthma
Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma.
Asthma
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
Asthma
Naturally Occurring Missense Mutation in Plasma PAF-AH Among the Japanese Population.
Asthma
PAF acetylhydrolase gene polymorphisms and asthma severity.
Asthma
PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency.
Asthma
Plasma platelet activating factor-acetylhydrolase (PAF-AH).
Asthma
Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma.
Asthma
Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy.
Asthma
Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.
Asthma
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
Asthma
Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model.
Asthma
The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.
Asthma
[Analysis of platelet-activating factor and its effect on the lung]
Asthma
[Increased plasma levels of platelet-activating factor (PAF) and low serum PAF acetylhydrolase (PAFAH) activity in adult patients with bronchial asthma]
Atherosclerosis
A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults.
Atherosclerosis
A pleiotropic QTL on 2p influences serum Lp-PLA2 activity and LDL cholesterol concentration in a baboon model for the genetics of atherosclerosis risk factors.
Atherosclerosis
A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass.
Atherosclerosis
A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease.
Atherosclerosis
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
Atherosclerosis
Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice.
Atherosclerosis
Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome.
Atherosclerosis
Ambient Air Pollution and Lipoprotein Associated Phospholipase A2 in Myocardial Infarction Survivors.
Atherosclerosis
Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40.
Atherosclerosis
Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2.
Atherosclerosis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Atherosclerosis
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Atherosclerosis
An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction.
Atherosclerosis
ANNALS EXPRESS: Lipoprotein-Associated Phospholipase A2: a new marker to determine cardiovascular risk in hypercholesterolemic dyslipidemic children.
Atherosclerosis
Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A? (Lp-PLA?): a review.
Atherosclerosis
ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.
Atherosclerosis
Apolipoprotein E-containing HDL-associated platelet-activating factor acetylhydrolase activities and malondialdehyde concentrations in patients with PCOS.
Atherosclerosis
Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study.
Atherosclerosis
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
Atherosclerosis
Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis.
Atherosclerosis
Association between the Lipoprotein-Associated Phospholipase A2 Activity and the Progression of Subclinical Atherosclerosis.
Atherosclerosis
Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.
Atherosclerosis
Association of lipoprotein-associated phospholipase A2 and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA).
Atherosclerosis
Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study.
Atherosclerosis
Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis.
Atherosclerosis
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Atherosclerosis
Association of PAF and its metabolic enzymes with GGT and the Fatty Liver Index in healthy volunteers.
Atherosclerosis
Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients.
Atherosclerosis
Association of Serum Lipoprotein-Associated Phospholipase A2 and A379V Gene Polymorphisms with Carotid Plaques.
Atherosclerosis
Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes.
Atherosclerosis
Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
Atherosclerosis
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
Atherosclerosis
Atherosclerosis assessment and rheumatoid arthritis.
Atherosclerosis
Characterization of Lipoprotein-associated Phospholipase A2 in Serum in Patients With Stage 3-5 Chronic Kidney Disease.
Atherosclerosis
Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.
Atherosclerosis
Clinical aspects of plasma platelet-activating factor-acetylhydrolase.
Atherosclerosis
Clinical Evaluation and Test of a Modified Lp-PLA2 Kit in Diagnosing Atherosclerosis.
Atherosclerosis
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Atherosclerosis
Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor.
Atherosclerosis
Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction.
Atherosclerosis
Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease.
Atherosclerosis
Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population.
Atherosclerosis
Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?
Atherosclerosis
Darapladib for the treatment of cardiovascular disease.
Atherosclerosis
Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
Atherosclerosis
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Atherosclerosis
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Atherosclerosis
Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2.
Atherosclerosis
Diabetes and Hypercholesterolemia Increase Blood-Brain Barrier Permeability and Brain Amyloid Deposition: Beneficial Effects of the LpPLA2 Inhibitor Darapladib.
Atherosclerosis
Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis.
Atherosclerosis
Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Atherosclerosis
Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
Atherosclerosis
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
Atherosclerosis
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.
Atherosclerosis
Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid.
Atherosclerosis
Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation.
Atherosclerosis
Expression of Hypoxia-Inducible Factor-1? (HIF1A) and Lp-PLA2 in Low, Intermediate, and High Cardiovascular Disease Risk Population.
Atherosclerosis
Expression of Lipoprotein associated phospholipase A2 enzyme in medical undergraduate students with metabolic syndrome.
Atherosclerosis
Free fatty acids to predict recurrent ischemic stroke.
Atherosclerosis
HDL capacity to inhibit LDL oxidation in well-trained triathletes.
Atherosclerosis
High density lipoprotein suppresses lipoprotein associated phospholipase A2 in human monocytes-derived macrophages through peroxisome proliferator-activated receptor-? pathway.
Atherosclerosis
Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
Atherosclerosis
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
Atherosclerosis
Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome.
Atherosclerosis
Impact of a non-synonymous Q281R polymorphism on structure of human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2 ).
Atherosclerosis
Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma.
Atherosclerosis
Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
Atherosclerosis
Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs.
Atherosclerosis
Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.
Atherosclerosis
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Atherosclerosis
Increased soluble vascular adhesion molecule-1 concentration is associated with impaired coronary flow reserve in cardiac syndrome X.
Atherosclerosis
Infection and inflammation-induced proatherogenic changes of lipoproteins.
Atherosclerosis
Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?
Atherosclerosis
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Atherosclerosis
Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.
Atherosclerosis
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Atherosclerosis
Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?
Atherosclerosis
Juvenile rheumatoid arthritis.
Atherosclerosis
Lentiviral-mediated RNA interference of lipoprotein-associated phospholipase A2 ameliorates inflammation and atherosclerosis in apolipoprotein E-deficient mice.
Atherosclerosis
Lifestyle modification induced weight loss and changes of cardiometabolic risk factors including lowering of inflammatory response in obese children.
Atherosclerosis
Lipids and lipoproteins and inflammatory markers in patients with chronic apical periodontitis.
Atherosclerosis
Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.
Atherosclerosis
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study.
Atherosclerosis
Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study).
Atherosclerosis
Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients.
Atherosclerosis
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Atherosclerosis
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-?) and their relation to premature atherosclerosis in ?-thalassemia children.
Atherosclerosis
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.
Atherosclerosis
Lipoprotein-associated phospholipase A2 (Lp-PLA_2): A novel and promising biomarker for cardiovascular risks assessment.
Atherosclerosis
Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.
Atherosclerosis
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.
Atherosclerosis
Lipoprotein-associated phospholipase A2 and coronary heart disease.
Atherosclerosis
Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study.
Atherosclerosis
Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study.
Atherosclerosis
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
Atherosclerosis
Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.
Atherosclerosis
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis.
Atherosclerosis
Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults.
Atherosclerosis
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases.
Atherosclerosis
Lipoprotein-associated phospholipase A2 as a target of therapy.
Atherosclerosis
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Atherosclerosis
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Atherosclerosis
Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis.
Atherosclerosis
Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population.
Atherosclerosis
Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study).
Atherosclerosis
Lipoprotein-Associated Phospholipase A2 Regulates Macrophage Apoptosis via the Akt and Caspase-7 Pathways.
Atherosclerosis
Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.
Atherosclerosis
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Atherosclerosis
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Atherosclerosis
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
Atherosclerosis
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Atherosclerosis
Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Atherosclerosis
Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Atherosclerosis
Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
Atherosclerosis
Lipoprotein-associated phospholipase A2: The story continues.
Atherosclerosis
Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy.
Atherosclerosis
Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
Atherosclerosis
Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.
Atherosclerosis
Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease.
Atherosclerosis
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Atherosclerosis
Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.
Atherosclerosis
Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
Atherosclerosis
Lp-PLA2 Inhibition-The Atherosclerosis Panacea?
Atherosclerosis
Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events.
Atherosclerosis
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.
Atherosclerosis
Lp-PLA2: an emerging biomarker of coronary heart disease.
Atherosclerosis
Maternal and fetal plasma platelet-activating factor-acetylhydrolase activity and distribution in pre-eclampsia.
Atherosclerosis
Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.
Atherosclerosis
Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.
Atherosclerosis
n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.
Atherosclerosis
Naturally Occurring Missense Mutation in Plasma PAF-AH Among the Japanese Population.
Atherosclerosis
New advances in drug discovery.
Atherosclerosis
New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
Atherosclerosis
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
Atherosclerosis
Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia.
Atherosclerosis
OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways.
Atherosclerosis
Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL.
Atherosclerosis
Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
Atherosclerosis
Periodontal microbiota and phospholipases: The Oral Infections and Vascular Disease Epidemiology Study (INVEST).
Atherosclerosis
Phospholipase A2 inhibitors.
Atherosclerosis
Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage.
Atherosclerosis
Plasma PAFAH/PLA2G7 Genetic Variability, Cardiovascular Disease, and Clinical Trials.
Atherosclerosis
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Atherosclerosis
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Atherosclerosis
Platelets inhibit the activity of platelet-activating factor acetylhydrolase in monocyte-derived macrophages.
Atherosclerosis
Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients.
Atherosclerosis
Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease.
Atherosclerosis
Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle.
Atherosclerosis
Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1? and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Atherosclerosis
Regression of atherosclerosis in apolipoprotein E-deficient mice by lentivirus-mediated gene silencing of lipoprotein-associated phospholipase A2.
Atherosclerosis
Regulation of lipoprotein-associated phospholipase A2 silencing on myocardial fibrosis in mice with coronary atherosclerosis.
Atherosclerosis
Relative sensitivities of plasma lecithin:cholesterol acyltransferase, platelet-activating factor acetylhydrolase, and paraoxonase to in vitro gas-phase cigarette smoke exposure.
Atherosclerosis
Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target.
Atherosclerosis
Role of lipoprotein-associated phospholipase A2 in atherosclerosis.
Atherosclerosis
Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.
Atherosclerosis
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
Atherosclerosis
SB-480848. GlaxoSmithKline.
Atherosclerosis
Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus.
Atherosclerosis
Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate- RhoA-p38 mitogen-activated protein kinase pathway.
Atherosclerosis
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Atherosclerosis
Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
Atherosclerosis
Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Atherosclerosis
Synthesis and Automated Labeling of [18F]Darapladib, a Lp-PLA2 Ligand, as Potential PET Imaging Tool of Atherosclerosis.
Atherosclerosis
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.
Atherosclerosis
The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
Atherosclerosis
The diagnostic efficacy and predictive value of combined lipoprotein laboratory indexes for atherosclerosis.
Atherosclerosis
The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction.
Atherosclerosis
The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.
Atherosclerosis
The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
Atherosclerosis
The Relationship Between Lipoprotein-Associated Phospholipase A(2), Cholesteryl Ester Transfer Protein and Lipid Profile and Risk of Atherosclerosis in Women with Iron Deficiency Anaemia.
Atherosclerosis
The relationship between lipoprotein-associated phospholipase A2 with cardiovascular risk factors in testosterone deficiency.
Atherosclerosis
The Role of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in Cardiovascular Disease.
Atherosclerosis
The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.
Atherosclerosis
The role of phospholipases in lipid modification and atherosclerosis.
Atherosclerosis
Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
Atherosclerosis
Utility of Lp-PLA2 in Lipid-Lowering Therapy.
Atherosclerosis
Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
Atherosclerosis
Vascular transcriptional alterations produced by juvenile obesity in Ossabaw swine.
Atherosclerosis
[Association of lipoprotein-associated phospholipase activity A2 with cardiovascular risk factors].
Atherosclerosis
[Cerebral atherosclerosis: a biomarker profile].
Atherosclerosis
[Changes of serum lipoprotein-related phospholipase A2 in patients with white matter lesion based on KIM classification and its correlation with carotid atherosclerotic plaque].
Atherosclerosis
[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Atherosclerosis
[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]
Atherosclerosis
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Atherosclerosis
[Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].
Atrial Fibrillation
Differential Effects of Serum Lipoprotein-Associated Phospholipase A2 on Periventricular and Deep Subcortical White Matter Hyperintensity in Brain.
Atrial Fibrillation
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Atrial Fibrillation
Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation.
Bacterial Infections
Lipoprotein-associated phospholipase A2, myeloperoxidase and vascular endothelial growth factor - predictors of high vascular risk in respiratory bacterial infections.
Basal Ganglia Hemorrhage
Serum lipoprotein-associated phospholipase A2 as a promising prognostic biomarker in association with 90-day outcome of acute intracerebral hemorrhage.
beta-Thalassemia
Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of beta-thalassemia/hemoglobin E patients.
Brain Diseases
Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality.
Brain Infarction
Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women.
Brain Ischemia
Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage.
Brain Ischemia
Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia.
Breast Neoplasms
Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer.
Breast Neoplasms
Cigarette smoke induces cell motility via platelet-activating factor accumulation in breast cancer cells: a potential mechanism for metastatic disease.
Breast Neoplasms
Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers.
Breast Neoplasms
Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity.
Breast Neoplasms
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Bronchopulmonary Dysplasia
Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia.
Calcinosis
A pattern of disperse plaque microcalcifications identifies a subset of plaques with high inflammatory burden in patients with acute myocardial infarction.
Carcinogenesis
Aberrant Expression of PAFAH1B3 Affects Proliferation and Apoptosis in Osteosarcoma.
Carcinogenesis
Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma.
Carcinogenesis
Diverse Functions of Plasma PAF-AH in Tumorigenesis.
Carcinogenesis
Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Carcinogenesis
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Carcinoma
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Carcinoma
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness.
Carcinoma
Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients.
Carcinoma, Hepatocellular
Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2.
Carcinoma, Hepatocellular
Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma.
Carcinoma, Squamous Cell
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Cardiac Complexes, Premature
Phospholipase A2 and Ischemic Stroke Etiology.
Cardiomyopathy, Dilated
Association of a G994-->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese.
Cardiomyopathy, Dilated
[Correlation between desmin gene, platelet-activating factor acetylhydrolase gene and dilated cardiomyopathy]
Cardiomyopathy, Hypertrophic
Association of a G994 --> T (Val279 --> Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy.
Cardiotoxicity
Radiation-induced lipoprotein-associated phospholipase A2 increases lysophosphatidylcholine and induces endothelial cell damage.
Cardiovascular Diseases
?3-polyunsaturated fatty acids suppress lipoprotein-associated phospholipase A2 expression in macrophages and animal models.
Cardiovascular Diseases
A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial.
Cardiovascular Diseases
A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT).
Cardiovascular Diseases
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
Cardiovascular Diseases
Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.
Cardiovascular Diseases
Ambient Air Pollution and Lipoprotein Associated Phospholipase A2 in Myocardial Infarction Survivors.
Cardiovascular Diseases
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Cardiovascular Diseases
Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A? (Lp-PLA?): a review.
Cardiovascular Diseases
Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NF?B pathways.
Cardiovascular Diseases
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
Cardiovascular Diseases
Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.
Cardiovascular Diseases
Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus.
Cardiovascular Diseases
Association between the Lipoprotein-Associated Phospholipase A2 Activity and the Progression of Subclinical Atherosclerosis.
Cardiovascular Diseases
Association of Lipoprotein-associated Phospholipase A(2) Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys.
Cardiovascular Diseases
Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
Cardiovascular Diseases
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
Cardiovascular Diseases
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Cardiovascular Diseases
Biomarkers for Prediction of Cardiovascular Events in Community-Dwelling Adults Aged 40 or Older.
Cardiovascular Diseases
Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome?
Cardiovascular Diseases
Characterization of PLAC® tests in the quantization of lipoprotein associated phospholipase A2 for assessment of cardiovascular diseases.
Cardiovascular Diseases
Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation.
Cardiovascular Diseases
Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.
Cardiovascular Diseases
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Cardiovascular Diseases
Clinical utility of lipoprotein-associated phospholipase A2 for cardiovascular disease prediction in a multiethnic cohort of women.
Cardiovascular Diseases
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
Cardiovascular Diseases
Comparison of Serum LP-PLA2 Level and some Nutritional Factors between Well-Controlled and Poorly-Controlled Diabetic Patients.
Cardiovascular Diseases
Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population.
Cardiovascular Diseases
Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.
Cardiovascular Diseases
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
Cardiovascular Diseases
Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease.
Cardiovascular Diseases
Developing and assessing cardiovascular biomarkers.
Cardiovascular Diseases
Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.
Cardiovascular Diseases
Effect of the R92H and A379V genotypes of platelet-activating factor acetylhydrolase on its enzyme activity, oxidative stress and metabolic profile in Chinese women with polycystic ovary syndrome.
Cardiovascular Diseases
Effects of A379V variant of the Lp-PLA 2 gene on Lp-PLA 2 activity and markers of oxidative stress and endothelial function in Koreans.
Cardiovascular Diseases
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Cardiovascular Diseases
Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration.
Cardiovascular Diseases
Effects of lipoprotein-associated phospholipase A2 on arginase/nitric oxide pathway in hemodialysis patients.
Cardiovascular Diseases
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Cardiovascular Diseases
Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.
Cardiovascular Diseases
Evaluation of lipoprotein-associated phosholipase A2 and plaque burden/composition in young adults.
Cardiovascular Diseases
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
Cardiovascular Diseases
Expression of Hypoxia-Inducible Factor-1? (HIF1A) and Lp-PLA2 in Low, Intermediate, and High Cardiovascular Disease Risk Population.
Cardiovascular Diseases
Expression of Lipoprotein associated phospholipase A2 enzyme in medical undergraduate students with metabolic syndrome.
Cardiovascular Diseases
Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.
Cardiovascular Diseases
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.
Cardiovascular Diseases
Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study).
Cardiovascular Diseases
High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
Cardiovascular Diseases
Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Cardiovascular Diseases
Impact of 8-week linoleic acid intake in soy oil on Lp-PLA2 activity in healthy adults.
Cardiovascular Diseases
Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?
Cardiovascular Diseases
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Cardiovascular Diseases
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).
Cardiovascular Diseases
Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients.
Cardiovascular Diseases
Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?
Cardiovascular Diseases
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study.
Cardiovascular Diseases
Lipoprotein phospholipase A2 in patients with isolated coronary artery ectasia.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
Cardiovascular Diseases
Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review.
Cardiovascular Diseases
Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 and risk stratification for cardiovascular disease: not ready for "prime time".
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases.
Cardiovascular Diseases
Lipoprotein-Associated Phospholipase A2 Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2: Review and recommendation of a clinical cut point for adults.
Cardiovascular Diseases
Lipoprotein-associated phospholipase A2 distribution among lipoproteins differs in type 1 diabetes.
Cardiovascular Diseases
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
Cardiovascular Diseases
Lp-PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke-risk populations.
Cardiovascular Diseases
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.
Cardiovascular Diseases
Measuring lipoprotein-associated phospholipase A2 activity in China: Protocol comparison and recalibration.
Cardiovascular Diseases
New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
Cardiovascular Diseases
On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management.
Cardiovascular Diseases
Overexpression of porcine lipoprotein-associated phospholipase A2 in swine.
Cardiovascular Diseases
Oxidized LDL induces procoagulant profiles by increasing lysophosphatidylcholine levels, lysophosphatidylethanolamine levels, and Lp-PLA2 activity in borderline hypercholesterolemia.
Cardiovascular Diseases
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Cardiovascular Diseases
Phospholipid mediators in the vessel wall: involvement in atherosclerosis.
Cardiovascular Diseases
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
Cardiovascular Diseases
Plasma PAFAH/PLA2G7 Genetic Variability, Cardiovascular Disease, and Clinical Trials.
Cardiovascular Diseases
Platelet-activating factor acetylhydrolases: An overview and update.
Cardiovascular Diseases
Relationship of lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in carotid atherosclerosis.
Cardiovascular Diseases
Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models.
Cardiovascular Diseases
Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease.
Cardiovascular Diseases
SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.
Cardiovascular Diseases
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Cardiovascular Diseases
Switching the substrate specificity of lysoplasmalogen-specific phospholipase D.
Cardiovascular Diseases
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.
Cardiovascular Diseases
Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting.
Cardiovascular Diseases
The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients.
Cardiovascular Diseases
The Association between Periodontal Status, Serum Lipid Levels, Lipoprotein Associated Phosholipase A2 (Lp-PLA2) in Chronic Periodontitis Subjects and Healthy Controls.
Cardiovascular Diseases
The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
Cardiovascular Diseases
The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice.
Cardiovascular Diseases
The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
Cardiovascular Diseases
The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of the lipoprotein-associated phospholipase A2-bound apoB.
Cardiovascular Diseases
The relation between Lp-PLA2 levels with periodic limb movements.
Cardiovascular Diseases
The relationship between dietary patterns and lipoprotein-associated phospholipase A2 levels in adults with cardiovascular risk factors: Tehran Lipid and Glucose Study.
Cardiovascular Diseases
The Role of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in Cardiovascular Disease.
Cardiovascular Diseases
The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review.
Cardiovascular Diseases
The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction.
Cardiovascular Diseases
The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men.
Cardiovascular Diseases
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Cardiovascular Diseases
Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
Cardiovascular Diseases
[Development and application of monoclonal antibodies anti-human lipoprotein-associated phospholipase A2].
Cardiovascular Diseases
[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Cardiovascular Diseases
[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]
Cardiovascular Diseases
[Lp-PLA2 and sPLA2: cardiovascular biomarkers].
Carotid Artery Diseases
Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study.
Carotid Artery Diseases
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
Carotid Artery Diseases
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Carotid Artery Diseases
Association of PLA2G7 polymorphisms with carotid atherosclerosis in hypertensive Japanese.
Carotid Artery Diseases
Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality.
Carotid Artery Diseases
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Carotid Artery Diseases
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.
Carotid Artery Diseases
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-?) and their relation to premature atherosclerosis in ?-thalassemia children.
Carotid Artery Diseases
Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Carotid Artery Diseases
Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.
Carotid Artery Diseases
Relationship of lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in carotid atherosclerosis.
Carotid Artery Diseases
Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
Carotid Stenosis
Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study.
Carotid Stenosis
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
Carotid Stenosis
Carotid Plaque Inflammation Assessed by 18F-FDG PET/CT and Lp-PLA2 Is Higher in Symptomatic Patients.
Carotid Stenosis
Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque.
Carotid Stenosis
Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome.
Carotid Stenosis
LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 AS A MARKER OF VULNERABLE ATHEROSCLEROTIC PLAQUE IN PATIENTS WITH INTERNAL CAROTID ARTERY STENOSIS.
Carotid Stenosis
Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Carotid Stenosis
Lp-PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke-risk populations.
Carotid Stenosis
Pro B-type Natriuretic Peptide and Midregional Proadrenomedullin are Associated with Incident Carotid Stenosis During Long Term Follow-up.
Carotid Stenosis
Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction.
Central Nervous System Infections
Platelet-activating factor acetylhydrolase activity in cerebrospinal fluid of children with acute systemic or neurological illness.
Cerebral Hemorrhage
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
Cerebral Hemorrhage
Serum lipoprotein-associated phospholipase A2 as a promising prognostic biomarker in association with 90-day outcome of acute intracerebral hemorrhage.
Cerebral Infarction
Carotid artery color Doppler ultrasonography and plasma levels of lipoprotein-associated phospholipase A2 and cystatin C in arteriosclerotic cerebral infarction.
Cerebral Infarction
Effects of dl-3-n-butylphthalide on serum lipoprotein-associated phospholipase A2 and hypersensitive C-reactive protein levels in acute cerebral infarction.
Cerebral Infarction
Evaluation of lipoprotein-associated phospholipase A2, serum amyloid A, and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction.
Cerebral Infarction
Platelet-activating factor and antiphospholipid antibodies in subarachnoid haemorrhage.
Cerebral Infarction
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Cerebral Infarction
Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction.
Cerebral Infarction
The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction.
Cerebral Infarction
[Analysis of 994(G--> T) mutation in the plasma platelet-activating factor acetylhydrolase gene in the patients with cerebral infarction]
Cerebral Small Vessel Diseases
Association of neuroimaging markers of cerebral small vessel disease with short-term outcomes in patients with minor cerebrovascular events.
Cerebral Small Vessel Diseases
Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment.
Cerebral Small Vessel Diseases
Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women.
Cerebrovascular Disorders
Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease.
Cerebrovascular Disorders
Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage.
Cerebrovascular Disorders
Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques.
Cerebrovascular Disorders
Lipoprotein phospholipase A2 mass and activity are not associated with the diagnosis of acute brain ischemia.
Cerebrovascular Disorders
Methylation of Phospholipase A2 Group VII Gene Is Associated with Brain Arteriovenous Malformations in Han Chinese Populations.
Cerebrovascular Disorders
Serum lipoprotein-associated phospholipase A2 as a promising prognostic biomarker in association with 90-day outcome of acute intracerebral hemorrhage.
Cerebrovascular Disorders
The emerging role of lipoprotein-associated phospholipase A2 in cerebrovascular disease.
Cholangiocarcinoma
MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
Cholangiocarcinoma
Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation.
Cholestasis
Serum PAF acetylhydrolase and chronic cholestasis.
Cholestasis
Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation.
Chondrocalcinosis
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Chronic Limb-Threatening Ischemia
Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.
Chronic Periodontitis
Activity of platelet activating factor acetylhydrolase following phase I periodontal therapy.
Chronic Periodontitis
Lipoprotein-associated phospholipase A2 and serum lipid levels in subjects with chronic periodontitis and hyperlipidemia.
Chronic Periodontitis
The Association between Periodontal Status, Serum Lipid Levels, Lipoprotein Associated Phosholipase A2 (Lp-PLA2) in Chronic Periodontitis Subjects and Healthy Controls.
Classical Lissencephalies and Subcortical Band Heterotopias
A novel neurological mutant mouse, yotari, which exhibits reeler-like phenotype but expresses CR-50 antigen/reelin.
Classical Lissencephalies and Subcortical Band Heterotopias
Characterization and chromosomal mapping of two pseudogenes of the mouse Pafaha/Lis1 gene: retrointegration hotspots in the mouse genome.
Classical Lissencephalies and Subcortical Band Heterotopias
Cloning and expression of a cDNA encoding the beta-subunit (30-kDa subunit) of bovine brain platelet-activating factor acetylhydrolase.
Classical Lissencephalies and Subcortical Band Heterotopias
Expression of a 45K subunit of platelet-activating factor acetylhydrolase in the developing mouse cerebellum.
Classical Lissencephalies and Subcortical Band Heterotopias
Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs.
Classical Lissencephalies and Subcortical Band Heterotopias
Miller-Dieker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase [corrected]
Classical Lissencephalies and Subcortical Band Heterotopias
PAFAH1B1 haploinsufficiency disrupts GABA neurons and synaptic E/I balance in the dentate gyrus.
Classical Lissencephalies and Subcortical Band Heterotopias
Predominant localization of the LIS family of gene products to Cajal-Retzius cells and ventricular neuroepithelium in the developing human cortex.
Classical Lissencephalies and Subcortical Band Heterotopias
The phospholipase complex PAFAH Ib regulates the functional organization of the Golgi complex.
Classical Lissencephalies and Subcortical Band Heterotopias
[Molecular mechanism of lissencephaly--how LIS1 and NDEL1 regulate cytoplasmic dynein?]
Coinfection
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Colitis, Ulcerative
Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis.
Colitis, Ulcerative
Relationship between the platelet activating factor acetylhydrolase gene and intractability of ulcerative colitis.
Colorectal Neoplasms
Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer.
Colorectal Neoplasms
Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients.
Coma
High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.
Corneal Edema
Corneal PAF acetylhydrolase increases in anterior segment ischemia in rabbits.
Coronary Artery Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Coronary Artery Disease
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Coronary Artery Disease
Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types.
Coronary Artery Disease
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).
Coronary Artery Disease
Association between Lipoprotein-Associated Phospholipase A(2) Gene Polymorphism and Coronary Artery Disease in the Chinese Han Population.
Coronary Artery Disease
Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis.
Coronary Artery Disease
Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis.
Coronary Artery Disease
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.
Coronary Artery Disease
Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians.
Coronary Artery Disease
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Coronary Artery Disease
Association of platelet-activating factor acetylhydrolase gene polymorphism with premature coronary artery disease in Turkish patients.
Coronary Artery Disease
Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
Coronary Artery Disease
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Coronary Artery Disease
Comparison of Change in Coronary Atherosclerosis in Patients With Stable Versus Unstable Angina Pectoris Receiving Statin Therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] Study).
Coronary Artery Disease
Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.
Coronary Artery Disease
Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease.
Coronary Artery Disease
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Coronary Artery Disease
Diabetes and Hypercholesterolemia Increase Blood-Brain Barrier Permeability and Brain Amyloid Deposition: Beneficial Effects of the LpPLA2 Inhibitor Darapladib.
Coronary Artery Disease
Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.
Coronary Artery Disease
Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease.
Coronary Artery Disease
Evaluation of lipoprotein-associated phosholipase A2 and plaque burden/composition in young adults.
Coronary Artery Disease
Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study).
Coronary Artery Disease
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Coronary Artery Disease
Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Coronary Artery Disease
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
Coronary Artery Disease
Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
Coronary Artery Disease
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Coronary Artery Disease
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Coronary Artery Disease
Letter regarding article by Winkler et al, "Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study".
Coronary Artery Disease
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Coronary Artery Disease
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids.
Coronary Artery Disease
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 levels are associated with erectile dysfunction in patients without known coronary artery disease.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target.
Coronary Artery Disease
Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Coronary Artery Disease
Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
Coronary Artery Disease
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
Coronary Artery Disease
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
Coronary Artery Disease
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.
Coronary Artery Disease
Plasma platelet-activating factor acetylhydrolase activity is not associated with premature coronary atherosclerosis.
Coronary Artery Disease
Plasma platelet-activating factor degradation in patients with severe coronary artery disease.
Coronary Artery Disease
Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease.
Coronary Artery Disease
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Coronary Artery Disease
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Coronary Artery Disease
Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction.
Coronary Artery Disease
Polyunsaturated Fatty Acids and Their Correlations with Parameters of Oxidative/Antioxidant Potential of the Blood and Lipoprotein-Associated Phospholipase A2 in Coronary Atherosclerosis.
Coronary Artery Disease
Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina.
Coronary Artery Disease
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Coronary Artery Disease
Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease.
Coronary Artery Disease
Regulation of lipoprotein-associated phospholipase A2 silencing on myocardial fibrosis in mice with coronary atherosclerosis.
Coronary Artery Disease
Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
Coronary Artery Disease
Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
Coronary Artery Disease
Structural Modeling of Wild and Mutant Forms of Human Plasma Platelet Activating Factor-Acetyl Hydrolase Enzyme.
Coronary Artery Disease
The diagnostic efficacy and predictive value of combined lipoprotein laboratory indexes for atherosclerosis.
Coronary Artery Disease
The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
Coronary Artery Disease
The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease.
Coronary Artery Disease
The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.
Coronary Artery Disease
Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.
Coronary Artery Disease
Utility of Lp-PLA2 in Lipid-Lowering Therapy.
Coronary Artery Disease
[Red blood cell distribution width combined with lipoprotein-associated phospholipase A2 detection for improving diagnostic accuracy of coronary artery stenosis in patients with coronary artery disease].
Coronary Disease
Advantages of the lipoprotein-associated phospholipase A2 activity assay.
Coronary Disease
Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types.
Coronary Disease
Association between Lp-PLA2 and coronary heart disease in Chinese patients.
Coronary Disease
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
Coronary Disease
Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population.
Coronary Disease
Biological variability of lipoprotein-associated phospholipase A2 activity in healthy individuals.
Coronary Disease
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
Coronary Disease
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Coronary Disease
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
Coronary Disease
Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor.
Coronary Disease
Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
Coronary Disease
Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.
Coronary Disease
Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.
Coronary Disease
Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females.
Coronary Disease
Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study: a case-control study.
Coronary Disease
Estrogen and promoter methylation in the regulation of PLA2G7 transcription.
Coronary Disease
Evaluation of recombinant enzyme calibration to harmonize lipoprotein-associated phospholipase A2 activity results between instruments.
Coronary Disease
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.
Coronary Disease
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study.
Coronary Disease
Interaction between nonsynonymous polymorphisms in PLA2G7 gene and smoking on the risk of coronary heart disease in a Chinese population.
Coronary Disease
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Coronary Disease
Lipids and lipoproteins and inflammatory markers in patients with chronic apical periodontitis.
Coronary Disease
Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.
Coronary Disease
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Coronary Disease
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
Coronary Disease
Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
Coronary Disease
Lipoprotein-associated phospholipase A2 and coronary heart disease.
Coronary Disease
Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.
Coronary Disease
Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.
Coronary Disease
Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
Coronary Disease
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases.
Coronary Disease
Lipoprotein-associated phospholipase A2 as a target of therapy.
Coronary Disease
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Coronary Disease
Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis.
Coronary Disease
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Coronary Disease
Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis.
Coronary Disease
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Coronary Disease
Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
Coronary Disease
Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
Coronary Disease
Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
Coronary Disease
Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease.
Coronary Disease
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Coronary Disease
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Coronary Disease
Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Coronary Disease
Lipoprotein-associated phospholipase A2: Review and recommendation of a clinical cut point for adults.
Coronary Disease
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Coronary Disease
Lp-PLA2: an emerging biomarker of coronary heart disease.
Coronary Disease
Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population.
Coronary Disease
Performance Characteristics and Clinical Value of the Lipoprotein-Associated Phospholipase A2 by an Enzymatic Kinetic Method.
Coronary Disease
Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population.
Coronary Disease
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Coronary Disease
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Coronary Disease
PLA2G7 gene polymorphisms and coronary heart disease risk: A meta-analysis.
Coronary Disease
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
Coronary Disease
PLAC Test for Lp-PLA2 Activity to Predict Coronary Heart Disease.
Coronary Disease
Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.
Coronary Disease
Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk.
Coronary Disease
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
Coronary Disease
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Coronary Disease
Study on the correlation between the concentration of plasma lipoprotein-associated phospholipase A2 and coronary heart disease.
Coronary Disease
Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China.
Coronary Disease
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.
Coronary Disease
The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction.
Coronary Disease
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Coronary Disease
The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
Coronary Disease
The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study.
Coronary Disease
Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
Coronary Disease
[Challenges in liver diseases and transplantation].
Coronary Disease
[Lipoprotein-associated phospholipase A2: importance and perspectives]
Coronary Stenosis
Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types.
Coronary Stenosis
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Coronary Stenosis
Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk.
Coronary Stenosis
[Red blood cell distribution width combined with lipoprotein-associated phospholipase A2 detection for improving diagnostic accuracy of coronary artery stenosis in patients with coronary artery disease].
COVID-19
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
Crohn Disease
PAF-acether and acetylhydrolase in stool of patients with Crohn's disease.
Crohn Disease
Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn's disease.
Cushing Syndrome
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Cushing Syndrome
CONDITIONING FACTORS FOR HIGH CARDIOVASCULAR RISK IN PATIENTS WITH CUSHING SYNDROME.
Cysts
No relation between biomarkers at age 47-49 and aortic diameter after 14-19 years of follow-up - a population-based study.
Delirium
Association of Carotid Plaque and Serum Lipoprotein-Associated Phospholipase A2 (LP-PLA2) with Postoperative Delirium in Geriatric Patients Undergoing Hip Replacement: A Prospective Cohort Study.
Dementia
A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease.
Dementia
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
Dementia
Inflammatory markers and the risk of dementia and Alzheimer's disease: A meta-analysis.
Dementia
Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study.
Dementia
Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
Dementia
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease.
Dementia
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
Dementia, Vascular
[Association of serum lipoprotein-associated phospholipase A2 with vascular dementia after ischemic stroke].
Dengue
Serum platelet-activating factor acetylhydrolase activity in dengue.
Dengue
[Serum platelet-activating factor acetylhydrolase activity in dengue patients of African or mestizo descendency].
Dermatitis, Atopic
Serum platelet-activating factor acetylhydrolase activity in patients with atopic dermatitis.
Diabetes Complications
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Diabetes Mellitus
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.
Diabetes Mellitus
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Diabetes Mellitus
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).
Diabetes Mellitus
Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus.
Diabetes Mellitus
Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia.
Diabetes Mellitus
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Diabetes Mellitus
Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
Diabetes Mellitus
Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2.
Diabetes Mellitus
Differential Effects of Serum Lipoprotein-Associated Phospholipase A2 on Periventricular and Deep Subcortical White Matter Hyperintensity in Brain.
Diabetes Mellitus
Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution.
Diabetes Mellitus
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Diabetes Mellitus
Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.
Diabetes Mellitus
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Diabetes Mellitus
Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects.
Diabetes Mellitus
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Diabetes Mellitus
Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitus.
Diabetes Mellitus
Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.
Diabetes Mellitus
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Diabetes Mellitus
Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus.
Diabetes Mellitus
Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease.
Diabetes Mellitus
Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: A prospective longitudinal cohort study.
Diabetes Mellitus
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Diabetes Mellitus
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus.
Diabetes Mellitus
Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.
Diabetes Mellitus
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Diabetes Mellitus
Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus.
Diabetes Mellitus
Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus.
Diabetes Mellitus
Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
Diabetes Mellitus
Role of vitamin D in risk factors of patients with type 2 diabetes mellitus.
Diabetes Mellitus
Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus.
Diabetes Mellitus
The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study.
Diabetes Mellitus
Type 5 and 6 nasal septal deformities: Could we predict and prevent acute coronary syndrome attacks in the future?
Diabetes Mellitus
[Lipoprotein-associated phospholipase A2 serum levels in patients from different categories of cardiovascular risk].
Diabetes Mellitus, Type 1
Altered platelet activating factor metabolism in insulin dependent diabetes mellitus.
Diabetes Mellitus, Type 1
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Diabetes Mellitus, Type 1
Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness.
Diabetes Mellitus, Type 1
Characterization of PAF-AH Ib1 in NOD mice: PAF-AH may not be a candidate gene of the diabetes susceptibility Idd4.1 locus.
Diabetes Mellitus, Type 1
Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetes.
Diabetes Mellitus, Type 1
Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes.
Diabetes Mellitus, Type 1
Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.
Diabetes Mellitus, Type 1
Lipoprotein-associated phospholipase A2 distribution among lipoproteins differs in type 1 diabetes.
Diabetes Mellitus, Type 1
Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes.
Diabetes Mellitus, Type 1
The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy.
Diabetes Mellitus, Type 1
The relationship between concentrations of magnesium and oxidized low density lipoprotein and the activity of platelet activating factor acetylhydrolase in the serum of patients with type 1 diabetes.
Diabetes Mellitus, Type 2
Altered platelet activating factor metabolism in insulin dependent diabetes mellitus.
Diabetes Mellitus, Type 2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Diabetes Mellitus, Type 2
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).
Diabetes Mellitus, Type 2
Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.
Diabetes Mellitus, Type 2
Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution.
Diabetes Mellitus, Type 2
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Diabetes Mellitus, Type 2
Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.
Diabetes Mellitus, Type 2
Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects.
Diabetes Mellitus, Type 2
Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes.
Diabetes Mellitus, Type 2
Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.
Diabetes Mellitus, Type 2
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) and Future Risk of Type 2 Diabetes: Results from the Cardiovascular Health Study.
Diabetes Mellitus, Type 2
Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.
Diabetes Mellitus, Type 2
Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.
Diabetes Mellitus, Type 2
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
Diabetes Mellitus, Type 2
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Diabetes Mellitus, Type 2
Lipoprotein-associated Phospholipase A2 Is Associated with Risk of Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.
Diabetes Mellitus, Type 2
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Diabetes Mellitus, Type 2
Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT).
Diabetes Mellitus, Type 2
Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Role of vitamin D in risk factors of patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus.
Diabetes Mellitus, Type 2
The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study.
Diabetes Mellitus, Type 2
[Diagnostic value of combined detection of different indicators for type 2 diabetes mellitus combined with atherosclerotic disease].
Diabetes, Gestational
Activity and distribution of plasma platelet-activating factor acetylhydrolase in women with gestational diabetes mellitus and their neonates.
Diabetes, Gestational
Application Value of Lipoprotein-Associated Phospholipase A2 Expression Level in Evaluating the Risk of Major Bleeding in Gestational Diabetes.
Diabetes, Gestational
Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.
Diabetes, Gestational
Maternal Gestational Diabetes Mellitus increases placental and foetal lipoprotein-associated Phospholipase A2 which might exert protective functions against oxidative stress.
Diabetes, Gestational
Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus.
Diabetes, Gestational
The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance.
Diabetic Foot
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Diabetic Nephropathies
Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Diabetic Retinopathy
"Association between platelet activating factor acetylhydrolase and diabetic retinopathy: Does inflammation affect the retinal status?".
Diabetic Retinopathy
Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients.
Diabetic Retinopathy
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.
Diabetic Retinopathy
Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study.
Digestive System Diseases
Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease.
Dyslipidemias
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
Dyslipidemias
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.
Dyslipidemias
Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
Dyslipidemias
Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia.
Dyslipidemias
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
Dyslipidemias
Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia.
Dyslipidemias
High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
Dyslipidemias
Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients.
Dyslipidemias
Juvenile exposure to a high fat diet promotes behavioral and limbic alterations in the absence of obesity.
Dyslipidemias
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Dyslipidemias
Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1? and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Dyslipidemias
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Dyslipidemias
Utility of Lp-PLA2 in Lipid-Lowering Therapy.
Dyslipidemias
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Encephalomyelitis
Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation.
Encephalomyelitis, Autoimmune, Experimental
Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation.
Endometriosis
Platelet-activating factor acetylhydrolase activity in peritoneal fluids of women with endometriosis.
Endotoxemia
Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver.
Enterocolitis, Necrotizing
Absorption of platelet-activating factor acetylhydrolase by rat intestine.
Enterocolitis, Necrotizing
Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis.
Enterocolitis, Necrotizing
Platelet-activating factor concentration in the stool of human newborns: effects of enteral feeding and neonatal necrotizing enterocolitis.
Enterocolitis, Necrotizing
Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis.
Enterocolitis, Necrotizing
Serum PAF acetylhydrolase increases during neonatal maturation.
Enterocolitis, Necrotizing
The prevalence of platelet activating factor acetylhydrolase single nucleotide polymorphisms in relationship to necrotizing enterocolitis in Northwest Louisiana infants.
Enterocolitis, Necrotizing
The prevention of necrotizing enterocolitis. The role of platelet-activating factor acetylhydrolase.
Enterocolitis, Necrotizing
The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis.
Epilepsy
Association between Ala379Val polymorphism of lipoprotein-associated phospholipase A2 and migraine without aura in Iranian population.
Erectile Dysfunction
Lipoprotein-associated phospholipase A2 levels are associated with erectile dysfunction in patients without known coronary artery disease.
Essential Hypertension
Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension.
Essential Hypertension
Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.
Essential Hypertension
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Fasciculation
Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs.
Fatty Liver
Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease.
Fatty Liver
Exploration of serum sensitive biomarkers of fatty liver in dairy cows.
Fetal Death
Effect of dexamethasone on rat plasma platelet activating factor acetylhydrolase during the perinatal period.
Foot Ulcer
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Glioma
The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction.
Glomerulonephritis
Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis.
Glomerulonephritis, IGA
Deregulated platelet-activating factor levels and acetylhydrolase activity in patients with idiopathic IgA nephropathy.
Glomerulonephritis, IGA
Genetics of immunoglobulin A nephropathy.
Glomerulonephritis, IGA
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy.
Glomerulonephritis, IGA
Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy.
Glucose Intolerance
Inhibition of Ca2+-independent phospholipase A2 results in insufficient insulin secretion and impaired glucose tolerance.
Glucose Intolerance
Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.
Heart Diseases
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Heart Diseases
Is there a relationship between small, dense LDL and lipoprotein--associated phospholipase A2 mass in dialysis patients?
Heart Diseases
Lipoprotein-associated phospholipase A2 (Lp-PLA2) - possible diagnostic and risk biomarker in chronic ischaemic heart disease.
Heart Diseases
Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans.
Heart Diseases
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Heart Diseases
Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
Heart Diseases
Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
Heart Diseases
The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population.
Heart Diseases
[Lipoprotein-associated phospholipase A(2) and stroke]
Heart Failure
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Heart Failure
Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam Study.
Heart Failure
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Heart Failure
Lp-PLA2 Antagonizes Left Ventricular Healing After Myocardial Infarction by Impairing the Appearance of Reparative Macrophages.
Heart Failure
Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community.
Hematologic Neoplasms
Fighting Cancer Stem Cell Fate by Targeting LIS1 a WD40 Repeat Protein.
Hemolytic-Uremic Syndrome
Platelet-activating factor acetylhydrolase gene mutation in Japanese children with Escherichia coli O157-associated hemolytic uremic syndrome.
Hemorrhagic Stroke
Lipoprotein-associated Phospholipase A2 during the Hyperacute Stage of Ischemic and Hemorrhagic Strokes.
Hepatitis B
Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.
HIV Infections
Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).
HIV Infections
Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
HIV Infections
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Homozygous Familial Hypercholesterolemia
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Hydrocephalus
Pafah1b2 mutations suppress the development of hydrocephalus in compound Pafah1b1; Reln and Pafah1b1; Dab1 mutant mice.
Hypercholesterolemia
A single nucleotide polymorphism in the plasma PAF acetylhydrolase gene and risk of atherosclerosis in Japanese patients with peripheral artery occlusive disease.
Hypercholesterolemia
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
Hypercholesterolemia
Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia.
Hypercholesterolemia
Diabetes and Hypercholesterolemia Increase Blood-Brain Barrier Permeability and Brain Amyloid Deposition: Beneficial Effects of the LpPLA2 Inhibitor Darapladib.
Hypercholesterolemia
High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
Hypercholesterolemia
Oxidized LDL induces procoagulant profiles by increasing lysophosphatidylcholine levels, lysophosphatidylethanolamine levels, and Lp-PLA2 activity in borderline hypercholesterolemia.
Hypercholesterolemia
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
Hypercholesterolemia
The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of the lipoprotein-associated phospholipase A2-bound apoB.
Hypercholesterolemia
Type 5 and 6 nasal septal deformities: Could we predict and prevent acute coronary syndrome attacks in the future?
Hyperemia
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease.
Hyperglycemia
The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity.
Hyperhomocysteinemia
The recent effects of small dose of folic acid on lipoprotein-associated phospholipase A2 and systolic blood pressure variability in coronary heart disease patients with hyperhomocysteinemia: A single-center prospective cohort study.
Hyperinsulinism
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Hyperlipidemias
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.
Hyperlipidemias
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Hyperlipidemias
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.
Hyperlipidemias
Lipoprotein-associated phospholipase A2 and serum lipid levels in subjects with chronic periodontitis and hyperlipidemia.
Hyperlipidemias
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Hyperlipidemias
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
Hyperlipidemias
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Hyperlipoproteinemia Type II
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Hyperlipoproteinemia Type II
Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.
Hyperlipoproteinemia Type II
Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Hypersensitivity
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014.
Hypersensitivity
Clinical significance of plasma PAF acetylhydrolase activity measurements as a biomarker of anaphylaxis: Cross-sectional study.
Hypersensitivity
Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.
Hypersensitivity
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Hypertension
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
Hypertension
Activity of platelet-activating-factor-acetylhydrolase and the nitric oxide metabolite level in the plasma of pregnant women who develop transient hypertension during later pregnancy.
Hypertension
Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus.
Hypertension
Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia.
Hypertension
Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients.
Hypertension
Association of sixty-one non-synonymous polymorphisms in forty-one hypertension candidate genes with blood pressure variation and hypertension.
Hypertension
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Hypertension
Comparison of serum Lp-PLA2 levels in ischemic stroke patients with H-type hypertension or non-H-type hypertension.
Hypertension
Differential Effects of Serum Lipoprotein-Associated Phospholipase A2 on Periventricular and Deep Subcortical White Matter Hyperintensity in Brain.
Hypertension
Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes.
Hypertension
Effects of overweight and the PLA2G7 V279F polymorphism on the association of age with systolic blood pressure.
Hypertension
Elevated Lipoprotein-Associated Phospholipase A2 Independently Affects Age-Related Increases in Systolic Blood Pressure: A Nested Case-Control Study in a Prospective Korean Cohort.
Hypertension
Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females.
Hypertension
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Hypertension
Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension.
Hypertension
Increased Lipoprotein-associated phospholipase A2 activity portends an increased risk of resistant hypertension.
Hypertension
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.
Hypertension
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Hypertension
Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China.
Hypertension
Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.
Hypertension
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Hypertension
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Hypertension
Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease.
Hypertension
Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: A prospective longitudinal cohort study.
Hypertension
Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
Hypertension
MicroRNA-212-5p and its target PAFAH1B2 suppress vascular proliferation and contraction via the downregulation of RhoA.
Hypertension
Negative association between lipoprotein associated phospholipase A2 activity and baroreflex sensitivity in subjects with high normal blood pressure and a positive family history of hypertension.
Hypertension
OS 01-01 ASSOCIATION OF Lp-PLA2 MASS AND AYSMPTOMATIC INTRACRANIAL AND EXTRACRANIAL ARTERIAL STENOSIS IN HYPERTENSION PATIENTS.
Hypertension
Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients.
Hypertension
Risk factors of atherosclerotic tissue types in single-vessel and intermediate coronary lesions: a cross-sectional study.
Hypertension
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
Hypertension
Type 5 and 6 nasal septal deformities: Could we predict and prevent acute coronary syndrome attacks in the future?
Hypertension, Pulmonary
Circulating plasma platelet activating factor in persistent pulmonary hypertension of the newborn.
Hypertriglyceridemia
Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.
Hypertriglyceridemia
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Hypertriglyceridemia
Glycoprotein Ibalpha polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients.
Hypertriglyceridemia
Infection and inflammation-induced proatherogenic changes of lipoproteins.
Hypertriglyceridemia
Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
Hypobetalipoproteinemias
Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.
Hypogonadism
The relationship between lipoprotein-associated phospholipase A2 with cardiovascular risk factors in testosterone deficiency.
Hypotension
Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase.
Infant, Newborn, Diseases
Serum PAF acetylhydrolase increases during neonatal maturation.
Infections
A Neutralizing Monoclonal IgG1 Antibody of Platelet-Activating Factor Acetylhydrolase SsE Protects Mice against Lethal Subcutaneous Group A Streptococcus Infection.
Infections
Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B.
Infections
Contemporary Pharyngeal and Invasive emm1 and Invasive emm12 Group A Streptococcus Isolates Exhibit Similar In Vivo Selection for CovRS Mutants in Mice.
Infections
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators.
Infections
Group A Streptococcus secreted esterase hydrolyzes platelet-activating factor to impede neutrophil recruitment and facilitate innate immune evasion.
Infections
High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.
Infections
In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response.
Infections
Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients.
Infections
Lipid mediators and vector infection: Trypanosoma rangeli inhibits Rhodnius prolixus hemocyte phagocytosis by modulation of phospholipase A2 and PAF-acetylhydrolase activities.
Infections
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
Infections
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Infections
Platelet-activating factor acetylhydrolase activity in cerebrospinal fluid of children with acute systemic or neurological illness.
Infections
Requirement and Synergistic Contribution of Platelet-Activating Factor Acetylhydrolase Sse and Streptolysin S to Inhibition of Neutrophil Recruitment and Systemic Infection by Hypervirulent
Infections
Serum platelet-activating factor acetylhydrolase and paraoxonase-1 activity in horses infected with Leptospira spp.
Infections
The Effect of the Leptin Receptor Q223R Polymorphism on the Host Transcriptome Following Infection with E. histolytica.
Infections
[Inflammation in atherosclerosis]
Inflammatory Bowel Diseases
Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory bowel disease.
Inflammatory Bowel Diseases
Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases.
Influenza, Human
High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.
Influenza, Human
Preliminary Proteomic Analysis of A549 Cells Infected with Avian Influenza Virus H7N9 and Influenza A Virus H1N1.
Influenza, Human
YesT: a new rhamnogalacturonan acetyl esterase from Bacillus subtilis.
Insulin Resistance
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Insulin Resistance
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Insulin Resistance
Comparison of Serum LP-PLA2 Level and some Nutritional Factors between Well-Controlled and Poorly-Controlled Diabetic Patients.
Insulin Resistance
CONDITIONING FACTORS FOR HIGH CARDIOVASCULAR RISK IN PATIENTS WITH CUSHING SYNDROME.
Insulin Resistance
Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practice.
Insulin Resistance
Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
Insulin Resistance
Effect of the R92H and A379V genotypes of platelet-activating factor acetylhydrolase on its enzyme activity, oxidative stress and metabolic profile in Chinese women with polycystic ovary syndrome.
Insulin Resistance
Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves.
Insulin Resistance
Juvenile exposure to a high fat diet promotes behavioral and limbic alterations in the absence of obesity.
Insulin Resistance
Resistin is an inflammatory marker of atherosclerosis in humans.
Insulin Resistance
[Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance.]
Insulinoma
The group VIA calcium-independent phospholipase A2 participates in ER stress-induced INS-1 insulinoma cell apoptosis by promoting ceramide generation via hydrolysis of sphingomyelins by neutral sphingomyelinase.
Intestinal Polyposis
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Intracranial Hemorrhages
[Association between platelet-activating factor acetylhydrolase gene polymorphism and intracranial hemorrhage in preterm infants].
Intracranial Thrombosis
Platelet-activating factor acetylhydrolase activity in red blood cell-stroma from patients with cerebral thrombosis.
Intracranial Thrombosis
Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke.
Irritable Bowel Syndrome
PAF-acether and acetylhydrolase in stool of patients with Crohn's disease.
Ischemic Attack, Transient
Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis.
Ischemic Attack, Transient
Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia.
Ischemic Attack, Transient
The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.
Ischemic Stroke
A novel prognosis prediction model, including cytotoxic T lymphocyte-associated antigen-4, ischemia-modified albumin, lipoprotein-associated phospholipase A2, glial fibrillary acidic protein, and homocysteine, for ischemic stroke in the Chinese hypertensive population.
Ischemic Stroke
Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease.
Ischemic Stroke
Association of Lp-PLA2 G994T gene polymorphism with risk of ischemic stroke in Chinese population.
Ischemic Stroke
Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients.
Ischemic Stroke
Association of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population.
Ischemic Stroke
Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy.
Ischemic Stroke
Associations of platelet-activating factor acetylhydrolase gene polymorphisms with risk of ischemic stroke.
Ischemic Stroke
Characterization of PLAC® tests in the quantization of lipoprotein associated phospholipase A2 for assessment of cardiovascular diseases.
Ischemic Stroke
Clinical Utility of the Serum Level of Lipoprotein-Related Phospholipase A2 in Acute Ischemic Stroke With Cerebral Artery Stenosis.
Ischemic Stroke
Comparison of serum Lp-PLA2 levels in ischemic stroke patients with H-type hypertension or non-H-type hypertension.
Ischemic Stroke
Free fatty acids to predict recurrent ischemic stroke.
Ischemic Stroke
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Ischemic Stroke
High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.
Ischemic Stroke
Inflammatory Biomarkers of Vascular Risk as Correlates of Leukoariosis.
Ischemic Stroke
Influence of lipoprotein-associated phospholipase A2 mass on prognosis value of baseline platelet count for clinical outcomes after acute ischemic stroke.
Ischemic Stroke
Link between lipoprotein-associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke.
Ischemic Stroke
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Ischemic Stroke
Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis.
Ischemic Stroke
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
Ischemic Stroke
Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study.
Ischemic Stroke
Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.
Ischemic Stroke
Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins.
Ischemic Stroke
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ischemic Stroke
Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
Ischemic Stroke
Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke.
Ischemic Stroke
Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden.
Ischemic Stroke
Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.
Ischemic Stroke
OS 01-01 ASSOCIATION OF Lp-PLA2 MASS AND AYSMPTOMATIC INTRACRANIAL AND EXTRACRANIAL ARTERIAL STENOSIS IN HYPERTENSION PATIENTS.
Ischemic Stroke
Phospholipase A2 and Ischemic Stroke Etiology.
Ischemic Stroke
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Ischemic Stroke
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
Ischemic Stroke
Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke.
Ischemic Stroke
Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability in ischemic stroke patients?
Ischemic Stroke
Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke.
Ischemic Stroke
Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke: Methodological issues.
Ischemic Stroke
Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity.
Ischemic Stroke
Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hypertension Patients.
Ischemic Stroke
Reply to: "Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke: Methodological issues".
Ischemic Stroke
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Ischemic Stroke
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
Ischemic Stroke
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Ischemic Stroke
The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.
Ischemic Stroke
The diagnostic and prognostic performance of Lp-PLA2 in acute ischemic stroke.
Ischemic Stroke
The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction.
Ischemic Stroke
[Association of serum lipoprotein-associated phospholipase A2 with vascular dementia after ischemic stroke].
Ischemic Stroke
[Clinical role of lipoprotein-associated phospholipase A2].
Ischemic Stroke
[Lipoprotein associated phospholipase A2].
Ischemic Stroke
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Ischemic Stroke
[Meta-analysis for the relationship between lipoprotein-associated phospholipase A2 and ischemic stroke].
Kidney Failure, Chronic
Effect of a single hemodialysis session on endothelial dysfunction.
Kidney Failure, Chronic
Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure.
Lecithin Cholesterol Acyltransferase Deficiency
Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration.
Leptospirosis
Decrease of plasma platelet-activating factor acetylhydrolase activity in lipopolysaccharide induced mongolian gerbil sepsis model.
Leptospirosis
Serum activity of platelet-activating factor acetylhydrolase is a potential clinical marker for leptospirosis pulmonary hemorrhage.
Lipid Metabolism Disorders
Application Value of Lipoprotein-Associated Phospholipase A2 Expression Level in Evaluating the Risk of Major Bleeding in Gestational Diabetes.
Lissencephaly
A de novo microdeletion involving PAFAH1B (LIS1) related to lissencephaly phenotype.
Lissencephaly
Characterization and chromosomal mapping of two pseudogenes of the mouse Pafaha/Lis1 gene: retrointegration hotspots in the mouse genome.
Lissencephaly
Direct association of LIS1, the lissencephaly gene product, with a mammalian homologue of a fungal nuclear distribution protein, rNUDE.
Lissencephaly
Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality.
Lissencephaly
Inhibition of calpain increases LIS1 expression and partially rescues in vivo phenotypes in a mouse model of lissencephaly.
Lissencephaly
Involvement of platelet-activating factor and LIS1 in neuronal migration.
Lissencephaly
Platelet-activating factor (PAF) acetylhydrolase activity, LIS1 expression, and seizures.
Lissencephaly
Previously uncharacterized roles of platelet-activating factor acetylhydrolase 1b complex in mouse spermatogenesis.
Lissencephaly
Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit.
Lissencephaly
Targeted disruption of intracellular type I platelet activating factor-acetylhydrolase catalytic subunits causes severe impairment in spermatogenesis.
Liver Cirrhosis, Biliary
Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation.
Liver Diseases
Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study.
Liver Diseases
Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease.
Liver Diseases
[Challenges in liver diseases and transplantation].
Liver Neoplasms
Downregulation of sorting nexin 10 is associated with overexpression of miR-30d during liver cancer progression in rats.
Lung Diseases
Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia.
Lung Diseases
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Lung Injury
Elevated truncated oxidized phospholipids as a factor exacerbating ALI in the aging lungs.
Lung Injury
Platelet-activating factor (PAF)-acetylhydrolase and PAF-like compounds in the lung: effects of hyperoxia.
Lung Neoplasms
Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Lung Neoplasms
Is there a role of platelet-activating factor in human lung cancer?
Lung Neoplasms
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Lupus Erythematosus, Systemic
PAF acetylhydrolase activities in human systemic lupus erythematosus and lupus-prone mice.
Lupus Erythematosus, Systemic
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Lyme Disease
Peroxidative metabolism of arachidonic acid in the course of Lyme arthritis.
Lymphatic Metastasis
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Lymphoma
Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.
Lymphoma
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Lymphoma
Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?
Lymphoma
Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma.
Lymphoma, B-Cell
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Macular Degeneration
Identification of candidate genes for human retinal degeneration loci using differentially expressed genes from mouse photoreceptor dystrophy models.
Macular Degeneration
Lipoprotein-associated phospholipase A2 and risk of age-related macular degeneration: the Rotterdam Study.
Macular Edema
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema: A 3-Month Placebo-Controlled Study.
Macular Edema
Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Macular Edema
Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.
Macular Edema
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.
Macular Edema
Lipoprotein-associated phospholipase A2: The story continues.
Macular Edema
Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Malformations of Cortical Development, Group II
Involvement of platelet-activating factor and LIS1 in neuronal migration.
Malformations of Cortical Development, Group II
Predominant localization of the LIS family of gene products to Cajal-Retzius cells and ventricular neuroepithelium in the developing human cortex.
Meningioma
Analysis of several PLA2 mRNA in human meningiomas.
Meningioma
Platelet-activating factor and human meningiomas.
Meningitis
Detection and characterization of 45 kDa platelet activating factor acetylhydrolase in cerebrospinal fluid of children with meningitis.
Metabolic Diseases
Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.
Metabolic Diseases
Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases.
Metabolic Syndrome
A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial.
Metabolic Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Metabolic Syndrome
Association of Lipoprotein-associated Phospholipase A(2) Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys.
Metabolic Syndrome
Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease.
Metabolic Syndrome
Carriage of the V279F homozygous genotype, a rare allele, within the gene encoding Lp-PLA2 leads to changes in circulating intermediate metabolites in individuals without metabolic syndrome.
Metabolic Syndrome
Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor.
Metabolic Syndrome
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Metabolic Syndrome
Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.
Metabolic Syndrome
Expression of Lipoprotein associated phospholipase A2 enzyme in medical undergraduate students with metabolic syndrome.
Metabolic Syndrome
Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Metabolic Syndrome
Higher circulating GlycA, a pro-inflammatory glycoprotein biomarker, relates to lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in diabetic or metabolic syndrome subjects.
Metabolic Syndrome
Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.
Metabolic Syndrome
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.
Metabolic Syndrome
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Metabolic Syndrome
Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases.
Metabolic Syndrome
Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.
Metabolic Syndrome
SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.
Metabolic Syndrome
Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus.
Metabolic Syndrome
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
Migraine Disorders
Association between Ala379Val polymorphism of lipoprotein-associated phospholipase A2 and migraine without aura in Iranian population.
Migraine without Aura
Association between Ala379Val polymorphism of lipoprotein-associated phospholipase A2 and migraine without aura in Iranian population.
Mucocutaneous Lymph Node Syndrome
A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease.
Mucocutaneous Lymph Node Syndrome
Elevated Levels of Platelet Activating Factor and Its Acetylhydrolase Indicate High Risk of Kawasaki Disease.
Mucocutaneous Lymph Node Syndrome
Serum Lp-PLA2 Level Predicting Coronary Artery Lesions in Children with Kawasaki Disease.
Mucocutaneous Lymph Node Syndrome
The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population.
Multiple Sclerosis
Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation.
Multiple Sclerosis
Lp-PLA2: Inflammatory Biomarker of Vascular Risk in Multiple Sclerosis.
Multiple Sclerosis
Platelet-activating factor acetylhydrolase gene polymorphism and its activity in Japanese patients with multiple sclerosis.
Myocardial Infarction
A pattern of disperse plaque microcalcifications identifies a subset of plaques with high inflammatory burden in patients with acute myocardial infarction.
Myocardial Infarction
Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.
Myocardial Infarction
Ambient Air Pollution and Lipoprotein Associated Phospholipase A2 in Myocardial Infarction Survivors.
Myocardial Infarction
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Myocardial Infarction
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
Myocardial Infarction
Association between Lp-PLA2 and coronary heart disease in Chinese patients.
Myocardial Infarction
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Myocardial Infarction
Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe.
Myocardial Infarction
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
Myocardial Infarction
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study.
Myocardial Infarction
Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction.
Myocardial Infarction
Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction.
Myocardial Infarction
Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
Myocardial Infarction
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.
Myocardial Infarction
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Myocardial Infarction
Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients.
Myocardial Infarction
Endothelial function after ST-elevation myocardial infarction in patients with high levels of high-sensitivity CRP and Lp-PLA2: A substudy of the RESPONSE randomized trial.
Myocardial Infarction
Free fatty acids to predict recurrent ischemic stroke.
Myocardial Infarction
High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.
Myocardial Infarction
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
Myocardial Infarction
Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow.
Myocardial Infarction
Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories.
Myocardial Infarction
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Myocardial Infarction
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Myocardial Infarction
Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community.
Myocardial Infarction
Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.
Myocardial Infarction
Lipoprotein-associated phospholipase A2 as a target of therapy.
Myocardial Infarction
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
Myocardial Infarction
Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
Myocardial Infarction
Lp-PLA2 Antagonizes Left Ventricular Healing After Myocardial Infarction by Impairing the Appearance of Reparative Macrophages.
Myocardial Infarction
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.
Myocardial Infarction
Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.
Myocardial Infarction
Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.
Myocardial Infarction
Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction.
Myocardial Infarction
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
Myocardial Infarction
Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells.
Myocardial Infarction
The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction.
Myocardial Infarction
The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
Myocardial Infarction
The Relationship Between the Level of Serum ESM-1 and Lp-PLA2 in Patients With Acute ST-Segment Elevation Myocardial Infarction.
Myocardial Infarction
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Myocardial Infarction
Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.
Myocardial Infarction
Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Myocardial Infarction
Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction.
Myocardial Infarction
Variability of serial lipoprotein-associated phospholipase A2 measurements in post myocardial infarction patients: results from the AIRGENE Study Center Augsburg.
Myocardial Infarction
Variation in plasma platelet-activating factor degradation and serum lipids after acute myocardial infarction.
Myocardial Infarction
[Clinical role of lipoprotein-associated phospholipase A2].
Myocardial Ischemia
Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.
Myocardial Ischemia
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Myocardial Ischemia
[Influence of Intensive Hypolipidemic Therapy on Blood Concentration of Lipoprotein-Associated Phospholipase A2 in Patients With Ischemic Heart Disease.]
Myoma
Platelet-activating factor acetylhydrolase isoforms I and II in human uterus. Comparisons with pregnant uterus and myoma.
Neoplasm Metastasis
Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers.
Neoplasm Metastasis
Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Neoplasm Metastasis
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness.
Neoplasm Metastasis
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
Neoplasm Metastasis
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Neoplasms
?3-polyunsaturated fatty acids suppress lipoprotein-associated phospholipase A2 expression in macrophages and animal models.
Neoplasms
Aberrant Expression of PAFAH1B3 Affects Proliferation and Apoptosis in Osteosarcoma.
Neoplasms
Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma.
Neoplasms
Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer.
Neoplasms
Analysis of the correlation between serum resistin and the variability of erythropoietin responsiveness in patients with chronic kidney disease.
Neoplasms
Association between FSP, CVHI, inflammatory cytokines and the incidence of primary stroke.
Neoplasms
Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy.
Neoplasms
Catechin Attenuates Coronary Heart Disease in a Rat Model by Inhibiting Inflammation.
Neoplasms
Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization.
Neoplasms
Correlations between PAF-acether and tumor necrosis factor in rheumatoid arthritis. Influence of parenteral corticosteroids.
Neoplasms
Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc Min/+ mice.
Neoplasms
Diagnostic marker signature for esophageal cancer from transcriptome analysis.
Neoplasms
Diverse Functions of Plasma PAF-AH in Tumorigenesis.
Neoplasms
Downregulation of sorting nexin 10 is associated with overexpression of miR-30d during liver cancer progression in rats.
Neoplasms
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
Neoplasms
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Neoplasms
Endotoxin and hypoxia-induced intestinal necrosis in rats: the role of platelet activating factor.
Neoplasms
Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation.
Neoplasms
Genetics of intracerebral hemorrhage: Insights from candidate gene approaches.
Neoplasms
Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer.
Neoplasms
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Neoplasms
In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response.
Neoplasms
Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma.
Neoplasms
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women.
Neoplasms
Inflammatory markers in hyperlipidemia: from experimental models to clinical practice.
Neoplasms
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-?) and their relation to premature atherosclerosis in ?-thalassemia children.
Neoplasms
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Neoplasms
MicroRNA-3613-3p functions as a tumor suppressor and represents a novel therapeutic target in breast cancer.
Neoplasms
Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness.
Neoplasms
Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
Neoplasms
New advances in drug discovery.
Neoplasms
No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease.
Neoplasms
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
Neoplasms
Overview of PAF-Degrading Enzymes.
Neoplasms
Oxidative damage in dengue fever.
Neoplasms
PAF and hematopoiesis. II. Elevated levels of plasma paf acetylhydrolase after rapid infusion of 5-fluorouracil in cancer patients.
Neoplasms
Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella.
Neoplasms
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Neoplasms
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Neoplasms
Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth.
Neoplasms
Radiation-induced lipoprotein-associated phospholipase A2 increases lysophosphatidylcholine and induces endothelial cell damage.
Neoplasms
Relation of multiple inflammatory biomarkers to incident atrial fibrillation.
Neoplasms
Relationship between plasma levels of type II phospholipase A2, PAF acetylhydrolase, endothelin-1, and thrombomodulin in patients with infected burns.
Neoplasms
Resistin is an inflammatory marker of atherosclerosis in humans.
Neoplasms
Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models.
Neoplasms
Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis.
Neoplasms
Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
Neoplasms
[Inflammation in atherosclerosis]
Neoplasms
[Role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome after coronary stenting].
Nephritis
No evidence for a putative involvement of platelet-activating factor in systemic lupus erythematosus without active nephritis.
Nephrotic Syndrome
Release of platelet-activating factor in systemic lupus erythematosus.
Nephrotic Syndrome
Urine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteins.
Nervous System Diseases
?-Lactones: A Novel Class of Ca2+-Independent Phospholipase A2 (Group VIA iPLA2) Inhibitors with Ability to Inhibit ?-Cell Apoptosis.
Neuroblastoma
Effect of retinoic acid on the Ca2+-independent phospholipase A2 in nuclei of LA-N-1 neuroblastoma cells.
Neuroinflammatory Diseases
Role of Ca2+-independent phospholipase A2 and n-3 polyunsaturated fatty acid docosahexaenoic acid in prostanoid production in brain: perspectives for protection in neuroinflammation.
Neutropenia
Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver.
Neutropenia
Endotoxin and hypoxia-induced intestinal necrosis in rats: the role of platelet activating factor.
Non-alcoholic Fatty Liver Disease
Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study.
Non-alcoholic Fatty Liver Disease
Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
[Challenges in liver diseases and transplantation].
Non-ST Elevated Myocardial Infarction
Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients.
Non-ST Elevated Myocardial Infarction
[Correlation between serum inflammatory cytokine levels and fibrous cap thickness of fibrofatty plaque in coronary culprit lesions].
Obesity
Application Value of Lipoprotein-Associated Phospholipase A2 Expression Level in Evaluating the Risk of Major Bleeding in Gestational Diabetes.
Obesity
Association of Lipoprotein-associated Phospholipase A(2) Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys.
Obesity
Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.
Obesity
Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children.
Obesity
Endothelial Dysfunction in Children With Obstructive Sleep Apnea Is Associated With Elevated Lipoprotein-Associated Phospholipase A2 Plasma Activity Levels.
Obesity
Expression of Lipoprotein associated phospholipase A2 enzyme in medical undergraduate students with metabolic syndrome.
Obesity
Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study.
Obesity
Lipoprotein-Associated Phospholipase A2 Mass and Activity and Risk of Cardiovascular Disease in a Population With High Prevalences of Obesity and Diabetes: The Strong Heart Study.
Obesity
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Obesity
Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.
Obesity, Abdominal
Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity.
Osteoarthritis
Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases.
Osteoarthritis
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Osteosarcoma
Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Ovarian Neoplasms
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Overweight
Effects of overweight and the PLA2G7 V279F polymorphism on the association of age with systolic blood pressure.
Overweight
Type 5 and 6 nasal septal deformities: Could we predict and prevent acute coronary syndrome attacks in the future?
Pancreatic Neoplasms
Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy.
Pancreatic Neoplasms
PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.
Pancreatitis
Beneficial effects of recombinant platelet-activating factor acetylhydrolase and BN 52021 on bacterial translocation in cerulein-induced pancreatitis.
Pancreatitis
Correlations Between LP-PLA2 Gene Polymorphisms and Susceptibility and Severity of Acute Pancreatitis in a Chinese Population.
Pancreatitis
Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis.
Pancreatitis
Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
Parkinson Disease
Identification of brain proteins that interact with 2-methylnorharman. An analog of the parkinsonian-inducing toxin, MPP+.
Parkinson Disease
Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson's Disease.
Peanut Hypersensitivity
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
Peanut Hypersensitivity
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
Peanut Hypersensitivity
Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.
Periodontal Diseases
Implication of PAF and acetylhydrolase (PAF-AH) activity in periodontal disease.
Periodontal Diseases
Lipoprotein-associated phospholipase A2 and plasma lipids in patients with destructive periodontal disease.
Periodontitis
Serum Lp-PLA2: as a novel viewpoint in periodontal treatment of hyperlipidaemics.
Periodontitis
Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke.
Periodontitis
The Association between Periodontal Status, Serum Lipid Levels, Lipoprotein Associated Phosholipase A2 (Lp-PLA2) in Chronic Periodontitis Subjects and Healthy Controls.
Peripheral Arterial Disease
Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.
Peripheral Arterial Disease
Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease.
Peripheral Arterial Disease
Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study.
Peripheral Arterial Disease
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis.
Peripheral Arterial Disease
Lipoprotein-associated phospholipase A2 predicts lower limb ischemia in hemodialysis subjects.
Peripheral Arterial Disease
Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease.
Plague
Prognostic Value of Serum LP-PLA2 and hs-CRP in Unstable Atherosclerotic Plaques.
Pleural Effusion
Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer.
Pleurisy
Anti-inflammatory properties of a platelet-activating factor acetylhydrolase.
Pleurisy
Hydrolysis of platelet activating factor and its methylated analogs by acetylhydrolases.
Pneumonia
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
Pneumonia
Human macrophages secrete platelet-activating factor acetylhydrolase. A mechanism for resolution of pulmonary inflammation.
Polycystic Ovary Syndrome
Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Polycystic Ovary Syndrome
Effect of the R92H and A379V genotypes of platelet-activating factor acetylhydrolase on its enzyme activity, oxidative stress and metabolic profile in Chinese women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome.
Polycystic Ovary Syndrome
[Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance.]
Polycystic Ovary Syndrome
[The activity of platelet activating factor acetylhydrolase and its metabolic profile in patients with polycystic ovary syndrome]
Postpartum Hemorrhage
Application Value of Lipoprotein-Associated Phospholipase A2 Expression Level in Evaluating the Risk of Major Bleeding in Gestational Diabetes.
Pre-Eclampsia
Association of the G994T and R92H genotypes of platelet-activating factor acetylhydrolase with risk of preeclampsia in Chinese women.
Pre-Eclampsia
Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia.
Pre-Eclampsia
Evaluation of maternal plasma platelet activating factor acetylhydrolase activity and mRNA expression in pre-eclampsia: a case control study.
Pre-Eclampsia
Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.
Pre-Eclampsia
Maternal and fetal plasma platelet-activating factor-acetylhydrolase activity and distribution in pre-eclampsia.
Pre-Eclampsia
Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia.
Pre-Eclampsia
[The Ala379Val polymorphism of platelet-activating factor acetylhydrolase gene in Chinese patients with pre-eclampsia].
Prediabetic State
Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.
Prehypertension
Associations among oxidative stress, Lp-PLA2 activity and arterial stiffness according to blood pressure status at a 3.5-year follow-up in subjects with prehypertension.
Primary Ovarian Insufficiency
Platelet-activating factor acetylhydrolase and premature ovarian failure.
Primary Ovarian Insufficiency
Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients.
Prostatic Neoplasms
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
Prostatic Neoplasms
Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms.
Prostatic Neoplasms
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.
Prostatic Neoplasms
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.
Prostatic Neoplasms
Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
Proteinuria
Adenovirus-mediated gene transfer and lipoprotein-mediated protein delivery of plasma PAF-AH ameliorates proteinuria in rat model of glomerulosclerosis.
Proteinuria
Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy.
Psoriasis
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Psoriasis
Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation.
Pulmonary Disease, Chronic Obstructive
Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis.
Pulmonary Disease, Chronic Obstructive
Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Purpura
[Association between platelet-activating factor acetylhydrolase gene polymorphisms and gastrointestinal bleeding in children with Henoch-Schönlein purpura].
Renal Insufficiency
Biomarkers of aortic bioprosthetic valve structural degeneration.
Renal Insufficiency, Chronic
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Renal Insufficiency, Chronic
Characterization of Lipoprotein-associated Phospholipase A2 in Serum in Patients With Stage 3-5 Chronic Kidney Disease.
Renal Insufficiency, Chronic
Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin.
Renal Insufficiency, Chronic
Evaluation of Lipoprotein-Associated Phospholipase A2 as a Prognostic Biomarker in Chronic Kidney Disease.
Renal Insufficiency, Chronic
PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
Renal Insufficiency, Chronic
Paricalcitol effects on activities and metabolism of Platelet Activating Factor and on inflammatory cytokines in hemodialysis patients.
Reperfusion Injury
Platelet activating factor acetylhydrolase decreases lung reperfusion injury.
Reperfusion Injury
Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury.
Respiratory Distress Syndrome
G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene and lung ultrasound score as prognostic markers in evaluating the outcome of acute respiratory distress syndrome.
Respiratory Distress Syndrome
Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome.
Respiratory Distress Syndrome
Platelet-activating factor acetylhydrolase and acute respiratory distress syndrome: unanswered questions.
Respiratory Distress Syndrome
Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome.
Respiratory Distress Syndrome
Platelet-activating factor in surfactant preparations.
Respiratory Distress Syndrome
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
Rheumatic Diseases
Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases.
Rheumatic Diseases
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Rhinitis
Phospholipase A2 mRNA expression in the nasal mucosa of healthy subjects and patients with seasonal allergic rhinitis.
Scabies
Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus.
Scabies
YesT: a new rhamnogalacturonan acetyl esterase from Bacillus subtilis.
Scleroderma, Systemic
Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis.
Seizures
Platelet-activating factor (PAF) acetylhydrolase activity, LIS1 expression, and seizures.
Sepsis
Decrease of plasma platelet-activating factor acetylhydrolase activity in lipopolysaccharide induced mongolian gerbil sepsis model.
Sepsis
Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis.
Sepsis
Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Sepsis
PAF acetylhydrolase and arachidonic acid metabolite levels in patients with sepsis.
Sepsis
Plasma platelet activating factor-acetylhydrolase (PAF-AH).
Sepsis
Plasma platelet-activating factor acetylhydrolase activity in critically ill patients.
Sepsis
Platelet-activating factor (PAF) acetylhydrolase activity, type II phospholipase A2, and cytokine levels in patients with sepsis.
Sepsis
Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.
Sepsis
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Sepsis
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
Sepsis
Relationships between plasma levels of type-II phospholipase A2, PAF-acetylhydrolase, leukotriene B4, complements, endothelin-1, and thrombomodulin in patients with sepsis.
Sepsis
The Systemic Mediator-Associated Response Test Identifies Patients in Failed Sepsis Clinical Trials Among Whom Novel Drugs Reduce Mortality.
Shock, Septic
Accumulation of platelet-activating factor acetylhydrolase in the peritoneal cavity of guinea pig after endotoxin shock.
Shock, Septic
Class A CpG Oligonucleotide Priming Rescues Mice from Septic Shock via Activation of Platelet-Activating Factor Acetylhydrolase.
Shock, Septic
Cloning, expression and characterization of plasma platelet-activating factor-acetylhydrolase from guinea pig.
Shock, Septic
Nitrite/nitrate (NOX) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock.
Shock, Septic
Purification and characterization of platelet-activating factor acetylhydrolase from peritoneal fluid obtained from guinea pigs after endotoxin shock.
Shock, Septic
The macrophage response to endotoxin requires platelet activating factor.
Sleep Apnea, Obstructive
Endothelial Dysfunction in Children With Obstructive Sleep Apnea Is Associated With Elevated Lipoprotein-Associated Phospholipase A2 Plasma Activity Levels.
Sleep Apnea, Obstructive
Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome.
Sleep Apnea, Obstructive
SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.
Spasm
Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm.
Spinal Cord Injuries
High seminal platelet-activating factor acetylhydrolase activity in men with spinal cord injury.
ST Elevation Myocardial Infarction
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
ST Elevation Myocardial Infarction
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.
ST Elevation Myocardial Infarction
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
ST Elevation Myocardial Infarction
Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.
ST Elevation Myocardial Infarction
Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.
ST Elevation Myocardial Infarction
The Relationship Between the Level of Serum ESM-1 and Lp-PLA2 in Patients With Acute ST-Segment Elevation Myocardial Infarction.
ST Elevation Myocardial Infarction
Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Stomach Ulcer
Serum platelet-activating factor acetylhydrolase activity in rats with gastric ulcers induced by water-immersion stress.
Stroke
A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.
Stroke
Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease.
Stroke
Advantages of the lipoprotein-associated phospholipase A2 activity assay.
Stroke
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Stroke
Association between FSP, CVHI, inflammatory cytokines and the incidence of primary stroke.
Stroke
Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.
Stroke
Association of neuroimaging markers of cerebral small vessel disease with short-term outcomes in patients with minor cerebrovascular events.
Stroke
Butyphthalide in the treatment of massive Cerebral Infarction.
Stroke
Clinical Utility of the Serum Level of Lipoprotein-Related Phospholipase A2 in Acute Ischemic Stroke With Cerebral Artery Stenosis.
Stroke
Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
Stroke
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.
Stroke
Free fatty acids to predict recurrent ischemic stroke.
Stroke
High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.
Stroke
High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
Stroke
High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.
Stroke
Hypothesis of "stroke-stop" formula: a tool for risk index determination in development of acute cerebrovascular disease in asymptomatic individuals with carotid stenosis.
Stroke
Impact of innate inflammation in population studies.
Stroke
Inflammatory markers and stroke.
Stroke
Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke.
Stroke
Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories.
Stroke
LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 AS A MARKER OF VULNERABLE ATHEROSCLEROTIC PLAQUE IN PATIENTS WITH INTERNAL CAROTID ARTERY STENOSIS.
Stroke
Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis.
Stroke
Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke.
Stroke
Lipoprotein-associated phospholipase A2 and risk of stroke.
Stroke
Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.
Stroke
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases.
Stroke
Lipoprotein-associated Phospholipase A2 during the Hyperacute Stage of Ischemic and Hemorrhagic Strokes.
Stroke
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
Stroke
Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study.
Stroke
Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
Stroke
Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins.
Stroke
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.
Stroke
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Stroke
Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
Stroke
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.
Stroke
Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Stroke
Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis.
Stroke
Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.
Stroke
Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population.
Stroke
Phospholipase A2 and Ischemic Stroke Etiology.
Stroke
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
Stroke
Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment.
Stroke
Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke.
Stroke
Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability in ischemic stroke patients?
Stroke
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Stroke
Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity.
Stroke
Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hypertension Patients.
Stroke
Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women.
Stroke
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.
Stroke
Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting.
Stroke
The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.
Stroke
The diagnostic and prognostic performance of Lp-PLA2 in acute ischemic stroke.
Stroke
The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction.
Stroke
The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.
Stroke
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Stroke
Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.
Stroke
When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
Stroke
[Cerebral atherosclerosis: a biomarker profile].
Stroke
[Lipoprotein-associated phospholipase A(2) and stroke]
Stroke
[Lipoprotein-associated phospholipase A2: relation to development of ischemic stroke in patients with essential hypertension].
Stroke
[Plasma platelet-activating factor acetylhydrolase (PAF-AH) deficiency as a risk factor for stroke]
Stroke, Lacunar
Differential Effects of Serum Lipoprotein-Associated Phospholipase A2 on Periventricular and Deep Subcortical White Matter Hyperintensity in Brain.
Stroke, Lacunar
[Analysis of 994(G--> T) mutation in the plasma platelet-activating factor acetylhydrolase gene in the patients with cerebral infarction]
Subarachnoid Hemorrhage
Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Is Admission Lipoprotein-Associated Phospholipase A2 a Novel Predictor of Vasospasm and Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage?
Subarachnoid Hemorrhage
Plasma Platelet Activating Factor-Acetylhydrolase Activity and the Levels of Free Forms of Bio-marker of Lipid Peroxidation in Cerebrospinal Fluid of Patients with Aneurysmal Subarachnoid Hemorrhage.
Subarachnoid Hemorrhage
Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage.
Systemic Vasculitis
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators.
Tangier Disease
Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.
Tangier Disease
The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).
Thalassemia
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-?) and their relation to premature atherosclerosis in ?-thalassemia children.
Thrombocytopenia
Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.
Thrombosis
Activation of PAF-acetylhydrolase by nicotine and cotinine and their possible involvement in arterial thrombosis.
Thrombosis
Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
Thrombosis
Effect of Selective Thrombus Aspiration on Serum Lipoprotein-Associated Phospholipase A2 in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention with High Thrombus Burden.
Thrombosis
Effects of the Ala379Val polymorphism of lipoprotein-associated phospholipase A2 on thrombosis and inflammation in hypertensive patients.
Thrombosis
Exclusion of the alpha2 subunit of platelet-activating factor acetylhydrolase 1b (PAFAH1B2) as a prothrombotic gene in a protein C-deficient kindred and population-based case-control sample.
Thrombosis
Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.
Thrombosis
Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.
Thrombosis
[Correlation between serum inflammatory cytokine levels and fibrous cap thickness of fibrofatty plaque in coronary culprit lesions].
Tooth Loss
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.
Tuberculosis, Pulmonary
Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma.
Uremia
Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis.
Uveitis
The role of lipoprotein-associated phospholipase A2 in a murine model of experimental autoimmune uveoretinitis.
Vascular Calcification
The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2.
Vascular Diseases
A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.
Vascular Diseases
A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults.
Vascular Diseases
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
Vascular Diseases
Impact of innate inflammation in population studies.
Vascular Diseases
Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs.
Vascular Diseases
Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
Vascular Diseases
Lipoprotein-Associated Phospholipase A2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults.
Vascular Diseases
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Vascular Diseases
Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis.
Vascular Diseases
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Vascular Diseases
Plasma platelet activating factor-acetylhydrolase (PAF-AH).
Vascular Diseases
Platelet-activating factor acetylhydrolase: is it good or bad for you?
Vascular Diseases
Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction.
Vascular Diseases
Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA?) and lipoprotein(a) (Lp(a)).
Vascular Diseases
Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease.
Vasospasm, Intracranial
Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?
Vasospasm, Intracranial
Platelet-activating factor and antiphospholipid antibodies in subarachnoid haemorrhage.
Venous Thromboembolism
Lipoprotein-associated phospholipase A2 and venous thromboembolism: A prospective study.
Venous Thrombosis
Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults.
Vertebrobasilar Insufficiency
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Virus Diseases
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Vitamin E Deficiency
Vitamin E differentially regulates the expression of peroxiredoxin-1 and -6 in alveolar type II cells.
Wound Infection
Relationship between plasma levels of type II phospholipase A2, PAF acetylhydrolase, endothelin-1, and thrombomodulin in patients with infected burns.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.1.1.47 1-alkyl-2-acetylglycerophosphocholine esterase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
